CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update

Delphine Réa, Andreas Hochhaus, Michael J. Mauro, Yosuke Minami, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong Wook Kim, Jane F. Apperley, Jorge E. Cortes, Andre Abdo, Laura Marie Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem Chaudhri, Lynette Chee, Valentin García-GutiérrezKoji Sasaki, Shruti Kapoor, Alex Allepuz, Sara Quenet, Véronique Bédoucha, Carla Boquimpani

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update'. Together they form a unique fingerprint.

Medicine & Life Sciences